Organon (OGN) Cash & Equivalents (2020 - 2026)

Organon's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 104.02% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 104.02% YoY), while the FY2025 annual figure was $574.0 million, down 14.96% from the prior year.
• Cash & Equivalents was $1.1 billion for Q1 2026 at Organon, up from $574.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.1 billion in Q1 2026 to a low of $326.0 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $621.2 million across 5 years, with a median of $599.0 million in 2025.
• Biggest YoY gain for Cash & Equivalents was 392.2% in 2022; the steepest drop was 50.5% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $706.0 million in 2022, then fell by 1.84% to $693.0 million in 2023, then dropped by 2.6% to $675.0 million in 2024, then decreased by 14.96% to $574.0 million in 2025, then jumped by 94.43% to $1.1 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.1 billion (Q1 2026), $574.0 million (Q4 2025), and $672.0 million (Q3 2025), per Business Quant data.